Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0OAVWU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
BCMA-024
|
|||||
| Synonyms |
BCMA 024; BCMA024
Click to Show/Hide
|
|||||
| Organization |
Sorrento Therapeutics, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Multiple myeloma [ICD11:2A83]
Clinical candidate
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
|
Antigen Info | ||||
| Payload Name |
Duostatin 5.2
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Proprietary Concortis linker
|
Linker Info | ||||
| Conjugate Type |
Fully human anti-BCMA monoclonal antibody was conjugated using proprietary Concortis linker-Duostatin 5.2 toxin technology.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.